EP Patent

EP3781132A1 — Apixaban formulations

Assigned to Bristol Myers Squibb Co · Expires 2021-02-24 · 5y expired

What this patent protects

Apixaban pharmaceutical formulation is provided. Also provided is a use of the apixaban formulation in treatment of a thromboembolic disorder.

USPTO Abstract

Apixaban pharmaceutical formulation is provided. Also provided is a use of the apixaban formulation in treatment of a thromboembolic disorder.

Drugs covered by this patent

Patent Metadata

Patent number
EP3781132A1
Jurisdiction
EP
Classification
—
Expires
2021-02-24
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.